Navigation Links
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
Date:2/18/2009

HUNTINGTON BEACH, California, and AMSTERDAM, February 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonstrating the direct predictive ability of its breast cancer recurrence test, MammaPrint(R), has been published in Breast Cancer Research and Treatment. Additionally, the study authors have been invited to present the data at the American Association for Cancer Research's 2009 Annual Meeting in Denver, Colorado.

"Our multi-study pool of patient data is maturing quickly and this is the first of a number of forthcoming publications showing MammaPrint's direct predictive ability for neoadjuvant and adjuvant chemotherapy regimens," commented Dr. Bernhard Sixt, Ph.D., President and Chief Executive Officer. "These findings considerably add to MammaPrint's well-established indirect predictive evidence for any chemotherapy, since MammaPrint is highly prognostic for early metastasis risk. Only early metastasis risk can be reduced by chemotherapy as shown by the Early Breast Cancer Trialists' Collaborative Group in their most recent 5-year update*. These new findings will further support our ongoing discussions with payers and guideline committees."

The study directly addresses a major concern expressed in an excellent review** on the impact of tumor gene expression profiling outcomes in patients with breast cancer recently published by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. In its recommendations EGAPP is particularly concerned by the lack of direct evidence linking tumor gene expression profiling to improved outcomes. The current study provides this evidence for MammaPrint and persuasively establishes this link.

About the study

The study was performed in collaboration with the Netherlands Cancer Institute and analyzed the association between the pathological complete respons
'/>"/>

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. Agendia Appoints VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... City, Utah (PRWEB) August 27, 2014 ... that will expand its current Salt Lake City manufacturing ... underway outside of Utah to ultimately create 1,000 new ... 20 years. , “Utah is home to hardworking ... whom can be credited with Varian’s success in the ...
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... mysteries is how plants survive impact by the ... rays, while using this energy for photosynthesis. The ... plant,s blades quickly dissipate the energy throughout the ... at DTU Physics have now managed to successfully ... bacteria contain light-absorbing proteins which play a role ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7DTU researchers film protein quake for the first time 2
... Ala. , May 12 Atherotech Inc. will exhibit its ... Scientific Sessions 2010. The meeting takes place May 13-16 at ... , , ... lipid test that routinely reports directly measured LDL-C, which is included in ...
... ,, RESEARCH TRIANGLE PARK, N.C. , May 12 ... Research Clinical Trials and Statistics Unit, is running the Intergroup Exemestane Study ... women with early breast cancer and a median follow-up period of 91 ... the data from multiple centers. , ...
... Indiana Seed Fund, Indiana ,s only targeted life sciences seed ... Indianapolis -based biotechnology start-up company focused on the development of ... , , , ... 5 million Americans suffer from Alzheimer,s disease (AD), a number that ...
Cached Biology Technology:Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 2Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 3Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 3BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 4
(Date:8/28/2014)... handful of bacterial culprits that may drive inflammatory bowel ... using patients, own intestinal immune responses as a guide. ... journal Cell . , Trillions of bacteria exist ... role in the development and progression of IBD. Yet ... species affect a person,s susceptibility to IBD and its ...
(Date:8/28/2014)... and his collaborators have developed an online analytic tool ... re-engineering cells for biomedical investigation. CellNet is a free-use ... stem cell engineering. Details of CellNet and its application ... papers in the journal Cell . , "This ... all types of cell-based investigations and can potentially offer ...
(Date:8/28/2014)... 28, 2014  Privacy Advocate and Senior Staff Attorney ... , joins the lineup of biometric and mobile commerce ... UnPlugged Executive Summit in Tampa, Florida ... announced speakers include Steven Rahman, Director, Technology and Strategy at ... Experian. The theme of this year,s event is Mobility ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... clinic at the University of Michigan, neurologist Joseph Corey, M.D., ... to disease or injury. He sees the pain, ... conditions cause and wishes he could give patients more ... he heads to his research lab at the VA Ann ...
... Tom Bowman, chairman of Bowman Design Group and president ... Carbon Mitigation for Every Business" at the 2012 Behavior, ... original research and the success of own company,s green ... by 65% and decreased annual operating costs by $9000 ...
... HOUSTON (Nov. 7, 2012) Administering stem cells derived ... after a heart attack is safe but does not improve ... supported by the National Institutes of Health (NIH). ... Evaluation (TIME), mirror a previous related study, LateTIME, which found ...
Cached Biology News:Stem cells + nanofibers = Promising nerve research 2Stem cells + nanofibers = Promising nerve research 3Bone marrow stem cells do not improve short-term recovery after heart attack 2Bone marrow stem cells do not improve short-term recovery after heart attack 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
MMP-1/8 (H-300)...
Biology Products: